To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Akela Pharma Repeats its Fentanyl TAIFUN® Preclinical Toxicology Studies
Akela Pharma Inc. has announced that as previously requested by the FDA, it has started over again the required inhalation toxicology studies. The studies performed at US based CRO are expected to produce results allowing Akela to start the longer term safety arm of the Fentanyl TAIFUN® Phase III clinical trial in patients in the second quarter of 2009.
"We are still on track to deliver the required toxicology studies results in time to allow us to meet our previously disclosed regulatory submission timelines of Q1-2010 for the E.U. and Q3-2010 for the U.S." said Dr. Halvor Jaeger, CEO of Akela Pharma Inc.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
